• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    France Clinical Trials Market

    ID: MRFR/HS/48506-HCR
    200 Pages
    Garvit Vyas
    September 2025

    France Clinical Trials Market Research Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Therapeutic Area (Oncology, Cardiology, Neurology, Infectious Diseases, Endocrinology) and By End Use (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    France Clinical Trials Market Research Report — Global Forecast till 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Table of Contents

    France Clinical Trials Market Summary

    The France Clinical Trials market is poised for substantial growth, projected to reach 3.48 USD Billion by 2035.

    Key Market Trends & Highlights

    France Clinical Trials Key Trends and Highlights

    • The market valuation is expected to increase from 1.98 USD Billion in 2024 to 3.48 USD Billion by 2035.
    • A compound annual growth rate (CAGR) of 5.26 percent is anticipated from 2025 to 2035.
    • The growth trajectory indicates a robust expansion in clinical trial activities within the region.
    • Growing adoption of innovative technologies due to increasing demand for efficient trial processes is a major market driver.

    Market Size & Forecast

    2024 Market Size 1.98 (USD Billion)
    2035 Market Size 3.48 (USD Billion)
    CAGR (2025-2035) 5.26%

    Major Players

    Synta, Covance, Castor EDC, Charles River Laboratories, Eurofins Scientific, Orchard Therapeutics, Wuxi AppTec, Syneos Health, Medidata Solutions, Boehringer Ingelheim, IQVIA, PPD, Clinique des Maladies Infectieuses, Parexel

    France Clinical Trials Market Trends

    The France Clinical Trials Market is facing significant jumps resulting from a focus on innovation as well as regulatory developments. The French government supports clinical trials with policies designed to facilitate paperwork and cut approval waiting times which has been shown to improve the effectiveness and speed at which new therapies are introduced. The rise of remote monitoring and telehealth is also a point of focus with the increased use of decentralized clinical trials because of France’s attitude towards patient access and inclusivity, which is especially important.

    In conjunction, there is an increase in the advocacy of personalized medicine in France, resulting in custom tailored treatment plans for patients through genetic profiling. This personalize medicine trend supports the country’s strong research institutions and universities, their inter-institutional cooperation between the academia and the industry is clinically innovative.

    Furthermore, the heightened focus on the patients and their specific needs is shifting the clinical study focus onto designing patient-centered trials and initiating greater effort to involve participants. The France healthcare R&D funding supports the growing French biotechnology and pharmaceutical industries, which provides abundant opportunity.

    Those programs combined with the presence of established pharmaceutical companies and emerging new ventures form a synergistic environment that is expected to flourish. The advancement of computer and information technology requires that artificial intelligence and big data analytics be applied to the methods of conducting clinical trials for optimal study design and patient recruitment.

    Considering the accumulation of market forces’ support, technological innovations, and strong research infrastructure, it enables France to assert itself as one of the leaders in the world clinical trials ecosystem.

    France Clinical Trials Market Drivers

    Market Segment Insights

    Get more detailed insights about France Clinical Trials Market Research Report — Global Forecast till 2035

    Regional Insights

    Key Players and Competitive Insights

    The France Clinical Trials Market is characterized by its dynamic competitive landscape, driven by robust demand for innovative medical solutions and advancements in healthcare technologies. As the pharmaceutical and biotechnology sectors continue to thrive in France, numerous companies are vying for a significant share of the clinical trials market, emphasizing the importance of strategic partnerships, advanced technology adoption, and regulatory compliance.

    A combination of local and global players contributes to a rich ecosystem that fosters research and development, ultimately leading to enhanced patient outcomes and therapeutic advancements. Furthermore, the involvement of government policies and incentives aimed at promoting clinical research adds an additional layer to the competitive environment, compelling players to enhance their capabilities and service offerings.

    Synta has established a notable presence in the France Clinical Trials Market, leveraging its strengths to facilitate clinical research engagements effectively. With a focus on innovative methodologies and patient-centric approaches, Synta’s ability to execute trials efficiently within regulatory frameworks is a key part of its competitive advantage.

    The company is well-regarded for its expertise in oncology research, which promises to enhance treatment options within the French healthcare system. Synta's commitment to quality assurance and its extensive network of clinical trial sites in France allows it to swiftly recruit and retain participants, thus addressing one of the critical challenges faced in the competitive arena of clinical trials.

    This optimized operational efficiency, along with a flexible service model, positions Synta favorably amongst competitors in the country. Covance holds a significant position in the France Clinical Trials Market through a diverse range of services offered, including drug development, preclinical services, and other related solutions.

    The company's strong market presence is amplified by its proficiency in managing complex clinical trial designs and its technological innovations that enhance data collection and analysis capabilities. Covance’s strengths are evident in its extensive experience, which enables it to navigate regulatory pathways smoothly while maintaining a commitment to patient safety and ethical standards.

    The company has also made strategic investments and engaged in mergers and acquisitions to expand its operational footprint in France, thereby improving its service offerings and market reach. Covance’s high-level expertise and resources allow for greater efficiency in trial execution, which ultimately positions it as a formidable player in the competitive landscape of clinical trials within the French market.

    Key Companies in the France Clinical Trials Market market include

    Industry Developments

    In recent developments within the France Clinical Trials Market, several companies have showcased growth and strategic movements. Covance has been expanding its service offerings, particularly in the realm of patient recruitment and retention strategies to enhance trial efficiency.

    In October 2023, Charles River Laboratories strengthened its position by enhancing its preclinical services in France, which is vital given the country's strong emphasis on biotechnology development. Orchard Therapeutics is reportedly focusing on advancing its gene therapy trials based in France, aligning with the country’s rising investment in rare disease research.

    Moreover, the merger between Syneos Health and a leading contract research organization in earlier months increased capacity and capabilities in clinical research across Europe including France. The French government is actively investing in Research and Development to make France a hub for clinical trials, with specific incentives introduced to attract sponsors.

    This has resulted in a favorable environment for companies like Eurofins Scientific and Wuxi AppTec, which are capitalizing on burgeoning biopharmaceutical innovations within France, reflecting significant market growth and a heightened focus on efficient clinical trial processes.

    Market Segmentation

    Clinical Trials Market Phase Outlook

    • Phase I
    • Phase II
    • Phase III
    • Phase IV

    Clinical Trials Market End Use Outlook

    • Pharmaceutical Companies
    • Biotechnology Companies
    • Contract Research Organizations

    Clinical Trials Market Study Design Outlook

    • Interventional
    • Observational
    • Expanded Access

    Clinical Trials Market Therapeutic Area Outlook

    • Oncology
    • Cardiology
    • Neurology
    • Infectious Diseases
    • Endocrinology

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2018 1.9(USD Billion)
    MARKET SIZE 2024 1.98(USD Billion)
    MARKET SIZE 2035 3.48(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 5.261% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Billion
    KEY COMPANIES PROFILED Synta, Covance, Castor EDC, Charles River Laboratories, Eurofins Scientific, Orchard Therapeutics, Wuxi AppTec, Syneos Health, Medidata Solutions, Boehringer Ingelheim, IQVIA, PPD, Clinique des Maladies Infectieuses, Parexel
    SEGMENTS COVERED Phase, Study Design, Therapeutic Area, End Use
    KEY MARKET OPPORTUNITIES Increased R&D investment, Growth in rare diseases, Expansion of personalized medicine, Enhanced digital technologies adoption, Strong government support initiatives
    KEY MARKET DYNAMICS increasing regulatory support, rising R&D investments, growing patient recruitment, technological advancements, emphasis on data integrity
    COUNTRIES COVERED France

    Market Highlights

    Author
    Garvit Vyas
    Analyst

    Explore the profile of Garvit Vyas, one of our esteemed authors at Market Research Future, and access their expert research contributions in the field of market research and industry analysis

    Leave a Comment

    FAQs

    What is the expected market size of the France Clinical Trials Market in 2024?

    The France Clinical Trials Market is expected to be valued at 1.98 billion USD in 2024.

    What will be the value of the France Clinical Trials Market by 2035?

    By 2035, the France Clinical Trials Market is projected to reach a value of 3.48 billion USD.

    What is the anticipated CAGR for the France Clinical Trials Market from 2025 to 2035?

    The anticipated compound annual growth rate (CAGR) for the France Clinical Trials Market from 2025 to 2035 is 5.261%.

    Which phase of clinical trials will have the highest value in 2035?

    In 2035, Phase III clinical trials are expected to hold the highest value at 1.12 billion USD.

    What is the market size for Phase I clinical trials in 2024?

    The market size for Phase I clinical trials is projected to be 0.52 billion USD in 2024.

    Who are the major players in the France Clinical Trials Market?

    Major players in the France Clinical Trials Market include Synta, Covance, and Charles River Laboratories among others.

    What is the estimated value of Phase II clinical trials by 2035?

    The estimated value of Phase II clinical trials is projected to be 0.76 billion USD by 2035.

    How much is the France Clinical Trials Market valued for Phase IV in 2024?

    The market for Phase IV clinical trials is valued at approximately 0.34 billion USD in 2024.

    What significant growth opportunities exist in the France Clinical Trials Market?

    Significant growth opportunities in the France Clinical Trials Market arise from increasing investments in research and development.

    What challenges does the France Clinical Trials Market face?

    The France Clinical Trials Market faces challenges including regulatory hurdles and patient recruitment issues.

    1. EXECUTIVE SUMMARY
    2. Market Overview
    3. Key Findings
    4. Market Segmentation
    5. Competitive Landscape
    6. Challenges and Opportunities
    7. Future Outlook
    8. MARKET INTRODUCTION
    9. Definition
    10. Scope of the study
    11. Research Objective
    12. Assumption
    13. Limitations
    14. RESEARCH METHODOLOGY
    15. Overview
    16. Data Mining
    17. Secondary Research
    18. Primary Research
    19. Primary Interviews and Information Gathering Process
    20. Breakdown of Primary Respondents
    21. Forecasting Model
    22. Market Size Estimation
    23. Bottom-Up Approach
    24. Top-Down Approach
    25. Data Triangulation
    26. Validation
    27. MARKET DYNAMICS
    28. Overview
    29. Drivers
    30. Restraints
    31. Opportunities
    32. MARKET FACTOR ANALYSIS
    33. Value chain Analysis
    34. Porter's Five Forces Analysis
    35. Bargaining Power of Suppliers
    36. Bargaining Power of Buyers
    37. Threat of New Entrants
    38. Threat of Substitutes
    39. Intensity of Rivalry
    40. COVID-19 Impact Analysis
    41. Market Impact Analysis
    42. Regional Impact
    43. Opportunity and Threat Analysis
    44. France Clinical Trials Market, BY Phase (USD Billion)
    45. Phase I
    46. Phase II
    47. Phase III
    48. Phase IV
    49. France Clinical Trials Market, BY Study Design (USD Billion)
    50. Interventional
    51. Observational
    52. Expanded Access
    53. France Clinical Trials Market, BY Therapeutic Area (USD Billion)
    54. Oncology
    55. Cardiology
    56. Neurology
    57. Infectious Diseases
    58. Endocrinology
    59. France Clinical Trials Market, BY End Use (USD Billion)
    60. Pharmaceutical Companies
    61. Biotechnology Companies
    62. Contract Research Organizations
    63. Competitive Landscape
    64. Overview
    65. Competitive Analysis
    66. Market share Analysis
    67. Major Growth Strategy in the Clinical Trials Market
    68. Competitive Benchmarking
    69. Leading Players in Terms of Number of Developments in the Clinical Trials Market
    70. Key developments and growth strategies
    71. New Product Launch/Service Deployment
    72. Merger & Acquisitions
    73. Joint Ventures
    74. Major Players Financial Matrix
    75. Sales and Operating Income
    76. Major Players R&D Expenditure. 2023
    77. Company Profiles
    78. Synta
    79. Financial Overview
    80. Products Offered
    81. Key Developments
    82. SWOT Analysis
    83. Key Strategies
    84. Covance
    85. Financial Overview
    86. Products Offered
    87. Key Developments
    88. SWOT Analysis
    89. Key Strategies
    90. Castor EDC
    91. Financial Overview
    92. Products Offered
    93. Key Developments
    94. SWOT Analysis
    95. Key Strategies
    96. Charles River Laboratories
    97. Financial Overview
    98. Products Offered
    99. Key Developments
    100. SWOT Analysis
    101. Key Strategies
    102. Eurofins Scientific
    103. Financial Overview
    104. Products Offered
    105. Key Developments
    106. SWOT Analysis
    107. Key Strategies
    108. Orchard Therapeutics
    109. Financial Overview
    110. Products Offered
    111. Key Developments
    112. SWOT Analysis
    113. Key Strategies
    114. Wuxi AppTec
    115. Financial Overview
    116. Products Offered
    117. Key Developments
    118. SWOT Analysis
    119. Key Strategies
    120. Syneos Health
    121. Financial Overview
    122. Products Offered
    123. Key Developments
    124. SWOT Analysis
    125. Key Strategies
    126. Medidata Solutions
    127. Financial Overview
    128. Products Offered
    129. Key Developments
    130. SWOT Analysis
    131. Key Strategies
    132. Boehringer Ingelheim
    133. Financial Overview
    134. Products Offered
    135. Key Developments
    136. SWOT Analysis
    137. Key Strategies
    138. IQVIA
    139. Financial Overview
    140. Products Offered
    141. Key Developments
    142. SWOT Analysis
    143. Key Strategies
    144. PPD
    145. Financial Overview
    146. Products Offered
    147. Key Developments
    148. SWOT Analysis
    149. Key Strategies
    150. Clinique des Maladies Infectieuses
    151. Financial Overview
    152. Products Offered
    153. Key Developments
    154. SWOT Analysis
    155. Key Strategies
    156. Parexel
    157. Financial Overview
    158. Products Offered
    159. Key Developments
    160. SWOT Analysis
    161. Key Strategies
    162. References
    163. Related Reports
    164. France Clinical Trials Market SIZE ESTIMATES & FORECAST, BY PHASE, 2019-2035 (USD Billions)
    165. France Clinical Trials Market SIZE ESTIMATES & FORECAST, BY STUDY DESIGN, 2019-2035 (USD Billions)
    166. France Clinical Trials Market SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2035 (USD Billions)
    167. France Clinical Trials Market SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD Billions)
    168. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    169. ACQUISITION/PARTNERSHIP
    170. MARKET SYNOPSIS
    171. FRANCE CLINICAL TRIALS MARKET ANALYSIS BY PHASE
    172. FRANCE CLINICAL TRIALS MARKET ANALYSIS BY STUDY DESIGN
    173. FRANCE CLINICAL TRIALS MARKET ANALYSIS BY THERAPEUTIC AREA
    174. FRANCE CLINICAL TRIALS MARKET ANALYSIS BY END USE
    175. KEY BUYING CRITERIA OF CLINICAL TRIALS MARKET
    176. RESEARCH PROCESS OF MRFR
    177. DRO ANALYSIS OF CLINICAL TRIALS MARKET
    178. DRIVERS IMPACT ANALYSIS: CLINICAL TRIALS MARKET
    179. RESTRAINTS IMPACT ANALYSIS: CLINICAL TRIALS MARKET
    180. SUPPLY / VALUE CHAIN: CLINICAL TRIALS MARKET
    181. CLINICAL TRIALS MARKET, BY PHASE, 2025 (% SHARE)
    182. CLINICAL TRIALS MARKET, BY PHASE, 2019 TO 2035 (USD Billions)
    183. CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2025 (% SHARE)
    184. CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019 TO 2035 (USD Billions)
    185. CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2025 (% SHARE)
    186. CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2019 TO 2035 (USD Billions)
    187. CLINICAL TRIALS MARKET, BY END USE, 2025 (% SHARE)
    188. CLINICAL TRIALS MARKET, BY END USE, 2019 TO 2035 (USD Billions)
    189. BENCHMARKING OF MAJOR COMPETITORS

    France Clinical Trials Market Segmentation

     

     

     

    • Clinical Trials Market By Phase (USD Billion, 2019-2035)

      • Phase I
      • Phase II
      • Phase III
      • Phase IV

     

    • Clinical Trials Market By Study Design (USD Billion, 2019-2035)

      • Interventional
      • Observational
      • Expanded Access

     

    • Clinical Trials Market By Therapeutic Area (USD Billion, 2019-2035)

      • Oncology
      • Cardiology
      • Neurology
      • Infectious Diseases
      • Endocrinology

     

    • Clinical Trials Market By End Use (USD Billion, 2019-2035)

      • Pharmaceutical Companies
      • Biotechnology Companies
      • Contract Research Organizations

     

     

     

     

     

     

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials